The findings confirmed that the nanocarrier delivery system could deliver CTLA-4-siRNA to CD4+ and CD8+ T cell subsets at tumor sites, while decreasing the proportion of suppressor Tregs among tumor-infiltrating lymphocytes (TILs), thereby increasing the antitumor immune response of tumor-infiltrating T cells [98]. The gene discussed is CD4; the disease is neoplasm.